Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia

BACKGROUND: Guadecitabine is a novel DNA methyltransferase (DNMT) inhibitor with improved pharmacokinetics and clinical activity in a subset of patients with relapsed/refractory acute myeloid leukemia (r/r AML), but identification of this subset remains difficult. METHODS: To search for biomarkers o...

詳細記述

保存先:
書誌詳細
出版年:Clin Epigenetics
主要な著者: Chung, Woonbok, Kelly, Andrew D., Kropf, Patricia, Fung, Henry, Jelinek, Jaroslav, Su, Xiang Yao, Roboz, Gail J., Kantarjian, Hagop M., Azab, Mohammad, Issa, Jean-Pierre J.
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2019
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6647096/
https://ncbi.nlm.nih.gov/pubmed/31331399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-019-0704-3
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料